Academic Journal
The urease E subunit vaccine stimulate the immune response versus Helicobacter pylori in animal model.
| Τίτλος: | The urease E subunit vaccine stimulate the immune response versus Helicobacter pylori in animal model. |
|---|---|
| Συγγραφείς: | Nikzad-Chaleshtori M; Department of Biology, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran., Asgari M; Biotechnology Research Center, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran., Rezaeizadeh G; Department of Microbiology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran., Aali F; Biotechnology Research Center, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran., Doosti A; Biotechnology Research Center, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran. doostiabbas2021@gmail.com. |
| Πηγή: | Immunologic research [Immunol Res] 2025 Apr 22; Vol. 73 (1), pp. 74. Date of Electronic Publication: 2025 Apr 22. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Humana Press Country of Publication: United States NLM ID: 8611087 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-0755 (Electronic) Linking ISSN: 0257277X NLM ISO Abbreviation: Immunol Res Subsets: MEDLINE |
| Imprint Name(s): | Publication: Totawa Nj : Humana Press Original Publication: Basel ; New York : S. Karger, [c1986- |
| Ιατρικοί όροι (MeSH): | Helicobacter pylori*/immunology , Helicobacter pylori*/physiology , Helicobacter Infections*/immunology , Helicobacter Infections*/prevention & control , Urease*/genetics , Urease*/immunology , Vaccines, DNA*/immunology , Vaccines, DNA*/genetics , Bacterial Vaccines*/immunology , Bacterial Vaccines*/genetics , Bacterial Proteins*/genetics , Bacterial Proteins*/immunology, Antibodies, Bacterial/blood ; Vaccines, Subunit/immunology ; Cytokines/metabolism ; Cytokines/blood ; Immunoglobulin G/blood ; Animals ; Mice ; Mice, Inbred BALB C ; Disease Models, Animal ; Female ; Humans |
| Περίληψη: | There is a strong association between Helicobacter pylori (H. pylori) and the occurrence of gastritis and gastric mucosal lymphoma in the human population. Vaccination is a viable preventive measure in light of the escalating issue of antibiotic resistance. The use of DNA vaccines presents a potentially effective approach. This study used the utilization of antigenic H. pylori urease E subunit (UreE) for the development of a DNA vaccine. The UreE gene was chemically cloned into pIRES2-DsRed-Express (pDNA), and PCR and restriction enzyme digestion verified the cloning. The immunogenicity and immune-protective efficacy of the vaccination were assessed in BALB/c mice. In contrast, blood samples from BALB/c mice inoculated with pDNA-UreE showed higher levels of IgG, IFN-γ, IL- 4, and IL- 17. Furthermore, stomach damage and bacterial loads were reduced, and BALB/c mice inoculated with pDNA-UreE exhibited a significant protection rate (87.5%) against the H. pylori challenge. pDNA-UreE generated a combination of Th1-Th2-Th17 immune responses, perhaps contributing to adequate protection. Based on our findings, using this DNA immunization as a preventive measure against H. pylori infection is a viable approach. (© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| Competing Interests: | Declarations. Consent for publication: All authors agree to publish. Ethics approval: This article does not contain any studies with human participants. The study was approved by the Ethics Committee of the Islamic Azad University of Shahrekord Branch in Iran (IR.IAU.SHK.REC.1401). Competing interests: The authors declare no competing interests. |
| References: | Pereira MI, Medeiros JA. Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas. World J Gastroenterol: WJG. 2014;20(3):684. (PMID: 10.3748/wjg.v20.i3.684245747423921478) Saxena A, Mukhopadhyay AK, Nandi SP. Helicobacter pylori: perturbation and restoration of gut microbiome. J Biosci. 2020;45:1–15. (PMID: 10.1007/s12038-020-00078-7) Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514–33. (PMID: 10.1111/apt.1349726694080) Matos R, Amorim I, Magalhães A, Haesebrouck F, Gärtner F, Reis CA. Adhesion of Helicobacter species to the human gastric mucosa: a deep look into glycans role. Front Mol Biosci. 2021;8:656439. (PMID: 10.3389/fmolb.2021.656439340268328138122) BangaNdzouboukou JL, Lei Q, Ullah N, Zhang Y, Hao L, Fan X. Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H pylori. Helicobacter. 2021;26(1):e12758. (PMID: 10.1111/hel.12758) Schoep TD, Fulurija A, Good F, Lu W, Himbeck RP, Schwan C, Marshall BJ. Surface properties of Helicobacter pylori urease complex are essential for persistence. PLoS One. 2010;5(11):e15042. (PMID: 10.1371/journal.pone.0015042211247832993952) Carlsohn E, Nyström J, Bölin I, Nilsson CL, Svennerholm AM. HpaA is essential for Helicobacter pylori colonization in mice. Infect Immun. 2006;74(2):920–6. (PMID: 10.1128/IAI.74.2.920-926.2006164287351360314) Pan X, Pan L. Protection against Helicobacter pylori infection in BALB/c mouse model by oral administration of multivalent epitope-based vaccine of cholera toxin B subunit-HUUC. Front Immunol. 2018;9:344572. (PMID: 10.3389/fimmu.2018.01003) Benoit S, Maier RJ. Dependence of Helicobacter pylori urease activity on the nickel-sequestering ability of the UreE accessory protein. J Bacteriol. 2003;185(16):4787–95. (PMID: 10.1128/JB.185.16.4787-4795.200312896998166491) Ansari S, Yamaoka Y. Survival of Helicobacter pylori in gastric acidic territory. Helicobacter. 2017;22(4):e12386. (PMID: 10.1111/hel.12386) Lee MH, Roussel Y, Wilks M, Tabaqchali S. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H pylori infection in mice. Vaccine. 2001;19(28–29):3927–35. (PMID: 10.1016/S0264-410X(01)00119-011427267) Rahimi E, Ameri M, Doosti A, Gholampour AR. Occurrence of toxigenic Vibrio parahaemolyticus strains in shrimp in Iran. Foodborne Pathog Dis. 2010;7(9):1107–11. Mejías-Luque R., & Gerhard M. (2017). Immune evasion strategies and persistence of Helicobacter pylori. Molecular Pathogenesis and Signal Transduction by Helicobacter pylori. 53–71. Rosenbaum P, Tchitchek N, Joly C, Rodriguez Pozo A, Stimmer L, Langlois S, Martinon F. Vaccine inoculation route modulates early immunity and consequently antigen-specific immune response. Frontiers Immunol. 2021;12:645210. (PMID: 10.3389/fimmu.2021.645210) Chehelgerdi M, Heidarnia F, Dehkordi FB, Chehelgerdi M, Khayati S, Khorramian-Ghahfarokhi M, Kabiri H. Immunoinformatic prediction of potential immunodominant epitopes from cagW in order to investigate protection against Helicobacter pylori infection based on experimental consequences. Funct Integr Genom. 2023;23(2):107. (PMID: 10.1007/s10142-023-01031-1) Azadbakht N, Doosti A, Jami MS. CRISPR/Cas9-mediated LINC00511 knockout strategies, increased apoptosis of breast cancer cells via suppressing antiapoptotic genes. Biol Proced Online. 2022;24(1):8. Liu KY, Shi Y, Luo P. Therapeutic efficacy of oral immunization with attenuated Salmonella typhimurium expressing Helicobacter pylori CagA, VacA and UreB fusion proteins in mice model. Vaccine. 2011;29(38):6679–85. (PMID: 10.1016/j.vaccine.2011.06.09921745524) Hobernik D, Bros M. DNA vaccines—how far from clinical use? Int J Mol Sci. 2018;19(11):3605. (PMID: 10.3390/ijms19113605304457026274812) Zhou WY, Shi Y, Wu C, Zhang WJ, Mao XH, Guo G, Zou QM. Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine. 2009;27(36):5013–9. (PMID: 10.1016/j.vaccine.2009.05.00919446591) Lee J, Kumar SA, Jhan YY, Bishop CJ. Engineering DNA vaccines against infectious diseases. Acta Biomater. 2018;15(80):31–47. (PMID: 10.1016/j.actbio.2018.08.033) Kim C, Hovakimyan A, Zagorski K, Antonyan T, Petrushina I, Davtyan H, Agadjanyan MG. Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies. NPJ Vaccines. 2022;7(1):1. (PMID: 10.1038/s41541-021-00424-2350133198748802) Kaveh-Samani A, Dalali S, Kaviani F, Piri-Gharaghie T, Doosti A. Oral administration of DNA alginate nanovaccine induced immune-protection against Helicobacter pylori in Balb/C mice. BMC Immunol. 2024;25(1):11. (PMID: 10.1186/s12865-024-00602-63831025010838413) Guo L, Yin R, Xu G, Gong X, Chang Z, Hong D, Liu K. Immunologic properties and therapeutic efficacy of a multivalent epitope-based vaccine against four Helicobacter pylori adhesins (urease, Lpp20, HpaA, and CagL) in Mongolian gerbils. Helicobacter. 2017;22(6):e12428. (PMID: 10.1111/hel.12428) Bosschem I, Bayry J, De Bruyne E, Van Deun K, Smet A, Vercauteren G, Flahou B. Effect of different adjuvants on protection and side-effects induced by Helicobacter suis whole-cell lysate vaccination. PloS One. 2015;10(6):e0131364. (PMID: 10.1371/journal.pone.0131364261153734482594) Mirzaei N, Poursina F, Moghim S, Rashidi N, GhasemianSafaei H. The study of H pylori putative candidate factors for single-and multi-component vaccine development. Crit Rev Microbiol. 2017;43(5):631–50. (PMID: 10.1080/1040841X.2017.129157828581361) Wilson CC, Newman MJ, Livingston BD, MaWhinney S, Forster JE, Scott J, Benson CA. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol. 2008;15(6):986–94. (PMID: 10.1128/CVI.00492-07184009762446619) De Groot AS, McMurry J, Marcon L, Franco J, Rivera D, Kutzler M, Martin B. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine. 2005;23(17–18):2121–31. (PMID: 15755582) Jafarzadeh A, Larussa T, Nemati M, Jalapour S. T cell subsets play an important role in the determination of the clinical outcome of Helicobacter pylori infection. Microb Pathog. 2018;116:227–36. (PMID: 10.1016/j.micpath.2018.01.04029407232) Romagnani S. Th1/th2 cells. Inflamm Bowel Dis. 1999;5(4):285–94. (PMID: 10.1097/00054725-199911000-0000910579123) Bagheri N, Salimzadeh L, Shirzad H. The role of T helper 1-cell response in Helicobacter pylori-infection. Microb Pathog. 2018;123:1–8. (PMID: 10.1016/j.micpath.2018.06.03329936093) Shi Y, Liu XF, Zhuang Y, Zhang JY, Liu T, Yin Z, Zou QM. Helicobacter pylori-induced Th17 responses modulate Th1 cell responses, benefit bacterial growth, and contribute to pathology in mice. J Immunol. 2010;184(9):5121–9. (PMID: 10.4049/jimmunol.090111520351183) Bretscher PA. On the mechanism determining the TH1/TH2 phenotype of an immune response, and its pertinence to strategies for the prevention, and treatment, of certain infectious diseases. Scand J Immunol. 2014;79(6):361–76. (PMID: 10.1111/sji.12175246845924282429) Moyat M, Velin D. Immune responses to Helicobacter pylori infection. World J Gastroenterol WJG. 2014;20(19):5583. (PMID: 10.3748/wjg.v20.i19.558324914318) Dooyema SD, Noto JM, Wroblewski LE, Piazuelo MB, Krishna U, Suarez G, Peek RM. Helicobacter pylori actively suppresses innate immune nucleic acid receptors. Gut Microbes. 2022;14(1):2105102. (PMID: 10.1080/19490976.2022.2105102359053769341374) Sutton P, Wilson J, Kosaka T, Wolowczuk I, Lee A. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies. Immunol Cell Biol. 2000;78(1):28–30. (PMID: 10.1046/j.1440-1711.2000.00881.x10651926) Fu HW, Lai YC. The role of Helicobacter pylori neutrophil-activating protein in the pathogenesis of H pylori and beyond: from a virulence factor to therapeutic targets and therapeutic agents. Int J Mol Sci. 2022;24(1):91. (PMID: 10.3390/ijms24010091366135429820732) Gu Q, Song D, Zhu M. Oral vaccination of mice against Helicobacter pylori with recombinant Lactococcus lactis expressing urease subunit B. FEMS Immunol Med Microbiol. 2009;56(3):197–203. (PMID: 10.1111/j.1574-695X.2009.00566.x194537507110364) Underwood W, Anthony R. 2020 AVMA guidelines for the euthanasia of animals: 2020 edition. Retrieved on March. Mar;2013(30):2020–1. Wang Y, Wang H. Lymph node targeting for immunotherapy. Immuno-Oncol Technol. 2023;1(20):100395. (PMID: 10.1016/j.iotech.2023.100395) Tufail S, Badrealam KF, Sherwani A, Gupta UD, Owais M. Tissue specific heterogeneity in effector immune cell response. Front Immunol. 2013;27(4):254. Brucklacher-Waldert V, Carr EJ, Linterman MA, Veldhoen M. Cellular plasticity of CD4+ T cells in the intestine. Front Immunol. 2014;7(5):488. |
| Contributed Indexing: | Keywords: Helicobacter pylori; DNA vaccine; Urease E subunit |
| Substance Nomenclature: | EC 3.5.1.5 (Urease) 0 (Vaccines, DNA) 0 (Bacterial Vaccines) 0 (Antibodies, Bacterial) 0 (Vaccines, Subunit) 0 (Bacterial Proteins) 0 (Cytokines) 0 (Immunoglobulin G) |
| Entry Date(s): | Date Created: 20250421 Date Completed: 20250421 Latest Revision: 20260204 |
| Update Code: | 20260204 |
| DOI: | 10.1007/s12026-025-09625-6 |
| PMID: | 40259189 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1559-0755 |
|---|---|
| DOI: | 10.1007/s12026-025-09625-6 |